呼吸器疾患の薬物療法を極める

出版社： 文光堂
著者：
発行日： 2018-04-13
分野： 臨床医学：内科  >  呼吸器一般
ISBN： 9784830617362
電子書籍版： 2018-04-13 （第1版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

7,150 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

7,150 円(税込)

購入する

商品紹介

呼吸器内科領域の薬物療法の進歩は近年，一層加速しており，各種ガイドラインは整備されているが，専門医でも最新知識をアップデートすることは容易ではない．本書では，各専門領域の第一線のエキスパートが，ガイドラインでは記載しきれない薬物療法のポイントを解説した実践的な内容となっている．最新の知見が，エキスパートオピニオンを交えて解説されており，実臨床に即した呼吸器疾患における薬物療法の「コツ」，「落とし穴」がふんだんに盛り込まれた1冊となった．

目次

  • I章　気管支喘息
    　ICS/LABAをどう使い分けるか？
    　ICS/LABAをどうステップダウンしていくか
    　ロイコトリエン受容体拮抗薬の有効症例は？
    　LAMA（長時間作用性吸入抗コリン薬）はどのような場面で使用するか
    　ドライパウダー製剤の種類別ピットフォールの予防法と対応
    　pMDI製剤・SMI製剤で生じるピットホールと対応法
    　上気道局所副作用症例への対応と処方選択薬
    　吸入ステロイド経鼻呼出法のエビデンスと薬剤選択
    　アレルギー性気管支肺アスペルギルス症に抗真菌薬はどのように使用するか
    　アレルゲン免疫療法の喘息における可能性
    　抗IgE抗体と抗IL-5抗体をどう使い分けるか
    　重症喘息に対する分子標的治療─現状と今後の展望─

    II章　COPD
    　吸入長時間作用性抗コリン薬（LAMA）製剤の特徴と使い分け
    　LAMA/LABA配合剤開始のタイミングと使い分け
    　喀痰調整薬のエビデンスと使い方
    　COPDに対する吸入ステロイド薬の有用性は好酸球数で見分けられるか？
    　β遮断薬使用は避けるべきか？
    　前立腺疾患合併例に対するLAMA投与の実際

    III章　喘息・COPDと周辺疾患
    　副鼻腔気管支症候群やびまん性汎細気管支炎に対するマクロライドの選択と治療期間
    　慢性閉塞性肺疾患（COPD）・喘息でどのような症例にマクロライドを用いるか
    　日常診療における慢性咳嗽の治療的診断

    IV章　間質性肺炎
    　抗線維化薬（ピルフェニドン，ニンテダニブ）をどう使い分けるか？
    　いつから，どのような症例に抗線維化薬を開始するか
    　抗線維化薬の臨床試験適応外症例への有効性
    　抗線維化薬（ニンテダニブ，ピルフェニドン）の有害事象と対応
    　特発性肺線維症に経口ステロイドを使ってはいけないのか
    　Nアセチルシステインのエビデンスと処方の実際
    　リコンビナントトロンボモジュリンの特発性肺線維症急性増悪における有用性と使い方
    　膠原病肺における免疫抑制薬の選択と使用法

    V章　肺　癌
    　一次治療におけるEGFR-TKIをどう選択するか？
    　EGFR-TKI再投与の実際
    　ALK阻害薬の使い方（治療シークエンスを含めて）
    　TPS≧50％における治療戦略
    　PD-L1発現1〜49％の非小細胞肺癌の二次治療以降の戦略
    　PD-L1発現1％未満の非小細胞肺癌の二次治療以降の戦略
    　ROS1陽性肺癌の治療展望
    　血管新生阻害薬の位置づけ
    　非小細胞肺癌脳転移に対する肺癌治療薬の効果の差異
    　間質性肺炎合併肺癌に対する薬剤選択
    　ペグフィルグラスチム使用の実際

    VI章　肺感染症
    　A．細菌感染症
    　B．抗酸菌症
    　C．その他

    VII章　肺循環/肺損傷
    　ARDSに対するステロイド，シベレスタット，抗凝固薬のエビデンス
    　呼吸器疾患に伴う肺高血圧症の薬物治療の考え方
    　肺

    VIII章　その他
    　肺炎球菌ワクチンの有効性と現在の使用適応についての考え方
    　プロトンポンプインヒビターの呼吸器疾患における有用性
    　禁煙治療薬の使い分けのポイント

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

I章 気管支喘息

P.7 掲載の参考文献
1) Global Initiative for Asthma (GINA) : Global strategy for asthma management and prevention (2017 update) : NHLBI/WHO Workshop report (http://www.ginasthma.com/) [Accessed : 2017. 11. 22]
 
2) 一般社団法人日本アレルギー学会喘息ガイドライン専門部会 (監) : 喘息予防・管理ガイドライン 2015. 協和企画, 2015
 
3) 新実彰男 : 吸入ステロイド薬の使い分け. アレルギー 65 : 757-63, 2016
Medical*Online
4) Price D, Roche N, Virchow CJ, et al : Device type and real-world effectiveness of asthma combination therapy : An observational study. Respir Med 105 : 1457-66, 2011
 
5) Hojo M, Shirai T, Iikura M, Hirashima J, Sugiyama H : Comparison of the clinical effects of combined salmeterol/fluticasone delivered by dry powder or pressurized metered dose inhaler. Pulm Pharmacol Ther 37 : 43-8, 2016
PubMed
6) Loymans RJ, Gemperli A, Cohen J, et al : Comparative effectiveness of long term drug treatment strategies to prevent asthma exacerbations : network meta-analysis. BMJ 348 : g3009, 2014
PubMed
P.12 掲載の参考文献
1) Hagan JB, Samant SA, Volcheck GW, et al : The risk of asthma exacerbation after reducing inhaled corticosteroids : a systematic review and meta-analysis of randomized controlled trials. Allergy 69 : 510-6, 2014
PubMed
2) Gionfriddo MR, Hagan JB, Hagan CR, et al : Stepping down inhaled corticosteroids from scheduled to as needed in stable asthma : Systematic review and meta-analysis. Allergy Asthma Proc 36 : 262-7, 2015
 
3) Tsurikisawa N, Oshikata C, Tsuburai T, et al : Markers for step-down of inhaled corticosteroid therapy in adult asthmatics. Allergol Int 61 : 419-29, 2012
PubMed
4) Tsurikisawa N, Oshikata C, Sato T, et al : Low variability in peak expiratory flow predicts successful inhaled corticosteroid stepdown in adult asthmatics. J Allergy Clin Immunol In Practice 2017 Dec 5, pii : S2213-2198 (17) 30883-8, doi : 10.1016/j. jaip, 2017. 10. 036
 
5) Westerhof GA, Coumou H, de Nijs SB, et al : Clinical predictors of remission and persistence of adult-onset asthma. J Allergy Clin Immunol 2017 Apr 22. pii : S0091-6749 (17) 30662-0. doi : 10.1016/j. jaci.2017. 03. 034
 
P.15 掲載の参考文献
1) Tomari S, Shimoda T, Kawano T, et al : Effects of pranlukast, a cysteinyl leukotriene receptor 1 antagonist, combined with inhaled beclomethasone in patients with moderate or severe asthma. Ann Allergy Asthma Immunol 87 : 156-61, 2001
PubMed
2) Price D, Musgrave SD, Shepstone L, et al : Leukotriene antagonists as first-line or add-on asthma-controller therapy. N Engl J Med 364 : 1695-707, 2011
PubMed
3) Matsuse H, Kohno S : Leukotriene receptor antagonists pranlukast and montelukast for treating asthma. Expert Opin Pharmacother 15 : 353-63, 2014
PubMed
4) Price DB, Swern A, Tozzi CA, et al : Effect of montelukast on lung function in asthma patients with allergic rhinitis : analysis from the COMPACT trial. Allergy 61 : 737-42, 2006
PubMed
5) Tamaoki J, Yokohori N, Tagaya E, et al : Comparable effect of a leukotriene receptor antagonist and long-acting beta2-adrenergic agonist in cough variant asthma. Allergy Asthma Proc 31 : 78-84, 2010
PubMed
6) Kelly MM, Chakir J, Vethanayagam D, et al : Montelukast treatment attenuates the increase in myofibroblasts following low-dose allergen challenge. Chest 130 : 741-53, 2006
PubMed
P.19 掲載の参考文献
1) Ohta K, Bousquet PJ, Aizawa H, et al : Prevalence and impact of rhinitis in asthma. SACRA, a cross-sectional nation-wide study in Japan. Allergy 66 : 1287-95, 2011
 
2) 杉本直也, 長瀬洋之, 小泉佑太ほか : 鼻炎関連症状の症状数・種類と喘息症状との関連. アレルギー 62 : 392, 2013
Medical*Online
3) Togias A : Rhinitis and asthma : evidence for respiratory system integration. J Allergy Clin Immunol 111 : 1171, 2003
PubMed
4) 一般社団法人日本アレルギー学会喘息ガイドライン専門部会監修 : 喘息予防・管理ガイドライン 2015. 東京, 協和企画, 2015
 
5) 鼻アレルギー診療ガイドライン作成委員会 : 鼻アレルギー診療ガイドライン-通年性鼻炎と花粉症-2016年版 (改訂第8版). 東京 : ライフサイエンス, 2015
 
6) Price DB, Swern A, Tozzi CA, et al : Effect of Montelukast on lung function in asthma patients with allergic rhinitis : analysis from the COMPACT trial. Allergy 61 : 737-42, 2006
PubMed
P.25 掲載の参考文献
1) Gosens R, Zaagsma J, Meurs H, et al : Muscarinic receptor signaling in the pathophysiology of asthma and COPD. Respir Res 7 : 73, 2006
PubMed
2) Kerstjens HA, Engel M, Dahl R, et al : Tiotropium in asthma poorly controlled with standard combination therapy. N Engl J Med 367 : 1198-207, 2012
PubMed
3) Peters SP, Kunselman SJ, Icitovic N, et al : Tiotropium bromide step-up therapy for adults with uncontrolled asthma. N Engl J Med 363 : 1715-26, 2010
PubMed
4) Paggiaro P, Halpin DM, Buhl R, et al : The effect of tiotropium in symptomatic asthma despite low- to medium-dose inhaled corticosteroids : A randomized controlled trial. J Allergy Clin Immunol Pract 4 : 104-13, 2016
PubMed
5) Kerstjens HA, Casale TB, Bleecker ER, et al : Tiotropium or salmeterol as add-on therapy to inhaled corticosteroids for patients with moderate symptomatic asthma : two replicate, double-blind, placebocontrolled, parallel-group, active-comparator, randomised trials. Lancet Respir Med 3 : 367-76, 2015
 
6) Ohta K, Ichinose M, Tohda Y, et al : Long-term once-daily tiotropium Respimat R is well tolerated and maintains efficacy over 52 weeks in patients with symptomatic asthma in Japan : A randomised, placebo-controlled study. PLoS One 10 : e0124109, 2015
 
7) Terada K, Terada T : The impact of tiotropium for exercise induced bronchoconstriction. Eur Respir J 50 : PA1808, 2017
 
8) Kerstjens HA, Moroni-Zentgraf P, Tashkin DP, et al : Tiotropium improves lung function, exacerbation rate, and asthma control, independent of baseline characteristics including age, degree of airway obstruction, and allergic status. Respir Med 117 : 198-206, 2016
PubMed
9) Casale TB, Bateman ED, Vandewalker M, et al : Tiotropium respimat add-on is efficacious in symptomatic asthma, independent of T2 phenotype. J Allergy Clin Immunol Pract, 2017 [Epub ahead of print]
 
10) Peters SP, Bleecker ER, Kunselman SJ, et al : Predictors of response to tiotropium versus salmeterol in asthmatic adults. J Allergy Clin Immunol 132 : 1068-74, 2013
PubMed
11) Bateman ED, Kornmann O, Schmidt P, et al : Tiotropium is noninferior to salmeterol in maintaining improved lung function in B16-Arg/Arg patients with asthma. J Allergy Clin Immunol 128 : 315-22, 2011
PubMed
12) Wechsler ME, Yawn BP, Fuhlbrigge AL, et al : Anticholinergic vs long-acting β-agonist in combination with inhaled corticosteroids in black adults with asthma : The BELT Randomized Clinical Trial. JAMA 314 : 1720-30, 2015
 
P.29 掲載の参考文献
1) Molimard M, Raherison C, Lignot S, et al : Chronic obstructive pulmonary disease exacerbation and inhaler device handling : real-life assessment of 2935 patients. Eur Respir J 49, 2017 (pii : 1601794)
 
2) 大道光秀, 大林浩幸, 沖 和彦ほか : COPD患者における吸気流速検査について. 日呼吸会誌 49 : 479-87, 2011
 
3) 須田茂明, 今野里緒, 黒澤一ほか : 慢性閉塞性肺疾患に使用される気管支拡張薬のドライパウダー吸入器の吸気抵抗. 日呼吸会誌 5 : 285-89, 2016
 
P.33 掲載の参考文献
1) 大林浩幸 : メカニズムから見る吸入デバイスのピットホール. p.34-144, 日経BP社, 2016
 
2) 堀口高彦, 近藤りえ子, 伴直昭ほか : 高齢者喘息の特徴を考慮した治療ナビゲーション-吸入薬の手技確認と理解度に関する検討-. アレルギー免疫 17 : 108-15, 2010
 
3) Ohbayashi H, Kudo S, Ishikawa M : Inhaler operability and patient satisfaction regarding Genuair and Respimat inhalers for chronic obstructive pulmonary disease : a randomized crossover study. Pulm Therapy 3 : 173-85, 2017
 
4) 大林浩幸 : 臨床現場における患者吸入指導のコツとそこに潜むピットホール. ファルマシア 48 : 290-5, 2012
 
P.36 掲載の参考文献
1) Wang PH, Wang HC, Cheng PW, et al : Hoarseness in asthmatic patients : the side effect of inhaled steroid or not? J Asthma 44 : 823-6, 2007
PubMed
2) Ozbilen Acar G, Uzun Adatepe N, Kaytaz A, et el : Evaluation of laryngeal findings in users of inhaled steroids. Eur Arch Otorhinolaryngol 267 : 917-23, 2010
 
3) 岡田章, 松本結希, 山越達也ほか : 吸入ステロイド薬の副作用である嗄声発現の要因解析. 医療薬学 40 : 716-25, 2014
Medical*Online
4) Ohbayashi H, Adachi M : Influence of dentures on residual inhaled corticosteroids in the mouths of elderly asthma patients. Resp Invest 5 : 54-61, 2012
 
5) Pitcairn G, Reader S, Pavia D, et al : Deposition of corticosteroid aerosol in the human lung by Respimat Soft Mist inhaler compared to deposition by metered dose inhaler or by Turbuhaler dry powder inhaler. J Aerosol Med 18 : 264-72, 2005
PubMed
P.41 掲載の参考文献
1) Amelink M, de Groot JC, de Nijs SB, et al : Severe adult-onset asthma : A distinct phenotype. J Allergy Clin Immunol 132 : 336-41, 2013
PubMed
2) de Groot JC, Storm H, Amelink M, et al : Clinical profile of patients with adult-onset eosinophilic asthma. ERJ Open Res 2. pii : 00100-2015. eCollection 2016 Apr.
 
3) Tokunaga T, Sakashita M, Haruna T, et al : Novel scoring system and algorithm for classifying chronic rhinosinusitis : the JESREC Study. Allergy 70 : 995-1003, 2015
PubMed
4) 安場広高 : Airway Medicine-上気道と下気道アレルギーの同時吸入療法. 耳鼻感染症・エアロゾル 5 : 1-4, 2017
 
5) 安場広高 : 難治性喘息における, 末梢気道閉塞と副鼻腔炎の関係と, HFA-BDP 経鼻呼出法による治療. 臨床免疫・アレルギー科 55 : 210-5, 2011
 
6) Tarsin WY, Pearson SB, Assi KH, et al : Emitted dose estimates from Seretide Diskus and Symbicort Turbuhaler following inhalation by severe asthmatics. Int J Pharm 316 : 131-7, 2006
PubMed
7) Pitcairn G, Reader S, Pavia D, et al : Deposition of corticosteroid aerosol in the human lung by Respimat Soft Mist inhaler compared to deposition by metered dose inhaler or by Turbuhaler dry powder inhaler. J Aerosol Med 18 : 264-72, 2005
PubMed
8) Hamada S, Matsumoto H, Kobayashi, Y, et al : Nasal exhalation of inhaled beclomethasone hydrofluoroalkine-134a to treat chronic rhinosinusitis. J Allergy Clin Immunol Pract 4 : 751-2, 2016
PubMed
9) Kobayashi Y, Asako M, Kanda A, et al : A novel therapeutic use of HFA-BDP metereddose inhaler for asthmatic patients with rhinosinusitis : Case series. Int J Clin Pharmacol Ther 52 : 914-9, 2014
PubMed
10) Kobayashi Y, Asako M, Yamamoto T, et al : Replacement of SFC-DPI with SFC-MDI exhaled through the nose improves eosinophilic chronic rhinosinusitis in patients with bronchial asthma. Int J Clin Pharmacol Ther 55 : 89-94, 2017
PubMed
11) 嶋貫和紗, 宮脇典子, 安場広高 : スギ花粉症合併喘息に対するHFA-BDP経鼻呼出法の効果pranlukast初期治療との比較. 三菱京都病院医総誌 18 : 13-7, 2011
 
12) Kobayashi Y, Asako M, Ooka H, et al : Residual exhaled nitric oxide elevation in asthmatics is associated with eosinophilic chronic rhinosinusitis. J Asthma 52 : 1060-4, 2015
PubMed
P.44 掲載の参考文献
1) Agarwal R, Chakrabarti A, Shah A, et al : Allergic bronchopulmonary aspergillosis : review of literature and proposal of new diagnostic and classification criteria. Clin Exp Allergy 43 : 850-73, 2013
PubMed
2) Li JX, Fan LC, Li MH, et al : Beneficial effects of Omalizumab therapy in allergic bronchopulmonary aspergillosis : A synthesis review of published literature. Respir Med 122 : 33-42, 2017
PubMed
3) Wark PA, Gibson PG, Wilson AJ : Azoles for allergic bronchopulmonary aspergillosis associated with asthma. Cochrane Database Syst Rev. 2004 ; (3) : CD001108. Review
PubMed
4) Moreira AS, Silva D, Ferreira AR, et al : Antifungal treatment in allergic bronchopulmonary aspergillosis with and without cystic fibrosis : a systematic review. Clin Exp Allergy 44 : 1210-27, 2014
 
5) Matsuse H, Tsuchida T, Fukahori S, et al : Dissociation between sensitizing and colonizing fungi in patients with allergic bronchopulmonary aspergillosis. Ann Allergy Asthma Immunol 111 : 190-3, 2013
PubMed
6) Denning DW, Park S, Lass-Florl C, et al : High-frequency triazole resistance found in nonculturable Aspergillus fumigatus from lungs of patients with chronic fungal disease. Clin Infect Dis 52 : 1123-9, 2011
PubMed
P.49 掲載の参考文献
1) 日本アレルギー学会「ダニアレルギーにおけるアレルゲン免疫療法の手引き」作成委員会 : ダニアレルギーにおけるアレルゲン免疫療法の手引き. メディカルレビュー, 2015
 
2) Abramson MJ, Puy RM, Weiner JM : Is allergen immunotherapy effective in asthma? A meta-analysis of randomized controlled trials. Am J Respir Crit Care Med 151 : 969-74, 1995
PubMed
3) Maestrelli P, Zanolla L, Pozzan M, et al : Regione Veneto Study Group on the "Effect of immunotherapy in allergic asthma". Effect of specific immunotherapy added to pharmacologic treatment and allergen avoidance in asthmatic patients allergic to house dust mite. J Allergy Clin Immunol 113 : 643-9, 2004
 
4) Jacobsen L, Niggemann B, Dreborg S, et al ; (The PAT investigator group) : Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma : 10-year follow-up on the PAT study. Allergy 62 : 943-8, 2007
PubMed
5) Virchow JC, Backer V, Kuna P, et al : Efficacy of a house dust mite sublingual allergen immunotherapy tablet in adults with allergic asthma : A randomized clinical trial. JAMA 315 : 1715-25, 2016
PubMed
6) Epstein TG, Liss GM, Murphy-Berendts K, et al : AAAAI/ACAAI Surveillance Study of Subcutaneous Immunotherapy, Years 2008-2012 : An update on fatal and nonfatal systemic allergic reactions. J Allergy Clin Immunol Pract. 2 : 161-7, 2014
PubMed
7) Eifan AO, Calderon MA, Durham SR : Allergen immunotherapy for house dust mite : clinical efficacy and immunological mechanisms in allergic rhinitis and asthma. Expert Opin Biol Ther 13 : 1543-56, 2013
PubMed
P.53 掲載の参考文献
1) Ortega HG, Liu MC, Pavord ID, et al : MENSA Investigators. Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med 371 : 1198-207, 2014
PubMed
2) Hanania NA, Wenzel S, Rosen K, et al : Exploring the effects of omalizumab in allergic asthma : an analysis of biomarkers in the EXTRA study. Am J Respir Crit Care Med 187 : 804-11, 2013
PubMed
3) Novelli F, Latorre M, Vergura L, et al : Xolair Italian Study Group. Asthma control in severe asthmatics under treatment with omalizumab : a cross-sectional observational study in Italy. Pulm Pharmacol Ther 31 : 123-9, 2015
 
4) Flood-Page P, Swenson C, Faiferman I, et al : International Mepolizumab Study Group. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am J Respir Crit Care Med 176 : 1062-71, 2007
 
5) Magnan A, Bourdin A, Prazma CM, et al : Treatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatment. Allergy 71 : 1335-44, 2016
PubMed
P.60 掲載の参考文献
1) 長瀬洋之 : 喘息における分子標的薬の可能性. アレルギー 64 : 14-22, 2015
Medical*Online
2) 路昭暉, 小泉佑太, 長瀬洋之ほか : 重症持続型喘息患者における分子標的薬 (Omalizumab, Mepolizumab) の適応症例の臨床背景について. アレルギー 66 : 531, 2017
 
3) 長瀬洋之 : 喘息に対する分子標的治療の現状と展望. 日小児アレルギー会誌 31 : 165-73, 2017
Medical*Online

II章 COPD

P.65 掲載の参考文献
1) 日本呼吸器学会COPDガイドライン第4版作成委員会編 : COPD (慢性閉塞性肺疾患) 診断と治療のためのガイドライン, 第4版, メディカルレビュー社, 2013
 
2) Tashkin DP, Celli B, Senn S, et al : A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 359 : 1543-54, 2008
PubMed
3) Tashkin DP, Celli B, Kesten S, et al : Long-term efficacy of tiotropium in relation to smoking status in the UPLIFT trial. Eur Respir J 35 : 287-94, 2010
PubMed
4) Yamamoto T, Iwase A, Araie M, et al : The Tajimi Study report 2 : prevalence of primary angle closure and secondary glaucoma in a Japanese population. Ophthalmology 112 : 1661-9, 2005
 
5) Sawaguchi S, Sakai H, Iwase A, et al : Prevalence of primary angle closure and primary angle-closure glaucoma in a southwestern rural population of Japan : the Kumejima Study. Ophthalmology 119 : 1134-42, 2012
 
P.72 掲載の参考文献
1) Disease GIfCCP. GOLD 2017 Global Strategy for the Diagnosis, Management and Prevention of COPD 2017 (http://goldcopd.org/gold-2017-global-strategy-diagnosis-management-prevention-copd/) [accessed : 2017. 11. 30]
 
2) Oba Y, Sarva ST, Dias S : Efficacy and safety of long-acting beta-agonist/long-acting muscarinic antagonist combinations in COPD : a network meta-analysis. Thorax 71 : 15-25, 2016
PubMed
3) Thomas M, Halpin DMG, Miravitlles M : When is dual bronchodilation indicated in COPD? Int J Chronic Obstr Pulm Dis 12 : 2291-305, 2017
 
4) Donohue JF, Singh D, Munzu C, et al : Magnitude of umeclidinium/vilanterol lung function effect depends on monotherapy responses : Results from two randomised controlled trials. Respir Med 112 : 65-74, 2016
PubMed
5) Jenkins CR, Postma DS, Anzueto AR, et al : Reliever salbutamol use as a measure of exacerbation risk in chronic obstructive pulmonary disease. BMC Pulm Med 15 : 97, 2015
PubMed
P.77 掲載の参考文献
1) Hogg JC : Pathophysiology of airflow limitation in COPD. Lancet 364 : 709-21, 2004
PubMed
2) Poole P, Chong J, Cates CJ : Mucolytics agents versus placebo for chronic bronchitis or chronic obstructive pulommnary disease. Cochran Database of Systematic Reviews 7, 2015 (CD001287)
PubMed
3) Wedzicha JA, Calverley PMA, Albert RK, et al : Prevention of COPD exacerbations : a European Respiratory Society/American Thoracic Society guideline. Eur Respir J 50, 2017 (pii : 1602265)
 
4) Zheng JP, Kang J, Huang SG, et al : Effects of carbocysteine on acute exacerbations of chronic obstructive pulmonary disease. Lancet 371 : 2013-8, 2008
PubMed
5) Malerba M, Ponticiello A, Radaeli A, et al : Effect of twelve-months therapy with oral ambroxol in preventing exacerbations in patients with COPD. Double-blind, randomized, multicenter, placebo-controlled study (the AMETHIST Trial). Pulm Pharmacol Ther 17 : 27-34, 2004
 
6) Dal Negro RW, Wedzicha JA, Iversen M, et al : Effect of erdosteine on the rate and duration of COPD exacerbations : the RESTORE study. Eur Respir J 50, 2017 (pii : 1700711)
 
7) Kesimer M, Ford AA, Ceppe A, et al : Airway mucin concentration as a marker of chronic bronchitis. N Engl J Med 377 : 911-22, 2017
PubMed
8) Fahy JV, Dickey BF : Airway mucus function and dysfunction. N Engl J Med 363 : 2233-47, 2010
PubMed
9) Woodruff PG, Barr RG, Bleecker E, et al : Clinical significance of symptoms in smokers with preserved pulmonary function. N Engl J Med 374 : 1811-21, 2016
PubMed
10) Kim V, Criner GJ : Chronic bronchitis and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 187 : 228-37, 2013
PubMed
P.81 掲載の参考文献
1) Watz H, Tetzlaff K, Wouters EF, et al : Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids : a post-hoc analysis of the WISDOM trial. Lancet Respir Med 4 : 390-8, 2016
PubMed
2) Global Initiative for Cronic Obstructive Lung Disease : http://goldcopd.org/gold-2017-global-strategydiagnosis-management-prevention-copd/ [accessed : 2017. 07. 31]
 
3) Roche N, Chapman KR, Vogelmeier CF, et al : Blood Eosinophils and Response to Maintenance COPD Treatment : Data from the FLAME Trial. Am J Respir Crit Care Med 195 : 1189-97, 2017
PubMed
P.85 掲載の参考文献
1) Loth DW, Brusselle GG, Lahousse L, et al : β-Adrenoceptor blockers and pulmonary function in the general population : the Rotterdam Study. Br J Clin Pharmacol 77 : 190, 2014
 
2) Salpeter SR, Ormiston TM, Salpeter EE : Cardioselective beta-blockers in patients with reactive airway disease : a meta-analysis. Ann Intern Med 137 : 715-25, 2002
PubMed
3) Lee DS, Markwardt S, McAvay GJ, et al : Effect of β-blockers on cardiac and pulmonary events and death in older adults with cardiovascular disease and chronic obstructive pulmonary disease. Med Care 52 : S45-S51, 2014
 
4) Bhatt SP, Wells JM, Kinney GL, et al : COPD Gene Investigators. β-Blockers are associated with a reduction in COPD exacerbations. Thorax 71 : 8-14, 2015
 
5) Du Q, Sun Y, Ding N, et al : Beta-blockers reduced the risk of mortality and exacerbation in patients with COPD : a meta-analysis of observational studies. PLoS One 9 : e113048, 2014
PubMed
P.88 掲載の参考文献
1) 日本薬局方 : アトロピン硫酸塩注射液 (2015年6月改訂)
 
2) スピリーバ(R) レスピマット添付文書 (2016年8月改訂)
 
3) Drug information of Spiriva. FDA, USA.
PubMed
4) 加藤元一, 草田詩恵, 小林岳彦ほか : 前立腺疾患合併COPD患者に対するチオトロピウムの投与 : 連続241症例の検討. 治療 91 : 187-91, 2009
 
5) 日本泌尿器学会 : 前立腺肥大症診療ガイドライン. リッチヒルメディカル, 2011
 

III章 喘息・COPDと周辺疾患

P.97 掲載の参考文献
1) 日本呼吸器学会咳嗽に関するガイドライン第2版作成委員会 : 咳嗽に関するガイドライン第2版. 日本呼吸器学会, p.39-41, 2012
 
2) Kudoh S, Azuma A, Asahiko M, et al : Improvement of survival in patients with diffuse panbronchiolitis treated with low-dose erythromycin. Am J Respir Crit Care Med 157 : 1829-32, 1998
 
3) Schultz MJ : Macrolide activities beyond their antimicrobial effects : macrolides in diffuse panbronchiolitis and cystic fibrosis. J Antimicrob Chemother 5 : 21-8, 2004
 
4) Gotfried MH : Macrolides for the treatment of chronic sinusitis, asthma, and COPD. Chest 125 : 52S-61S, 2004
PubMed
5) Haworth CS, Bilton D, Elborm JS : Long-term macrolide maintenance therapy in non-CF bronchiectasis : Evidence and questions. Respir Med 108 : 1397-408, 2014
 
6) Komiya K, Kurashima A, Ihi T, et al : Long-term, low-dose erythromycin monotherapy for Mycobacterium avium complex lung disease : a propensity score analysis. Int J Antimicrob Agents 44 : 131-5, 2014
PubMed
P.102 掲載の参考文献
1) Shinkai M, Henke MO, Rubin BK : Macrolide antibiotics as immunomodulatory medications : proposed mechanisms of action. Pharmacol Ther 117 : 393-405, 2008
PubMed
2) Shinkai M, Foster GH, Rubin BK : Macrolide antibiotics modulate ERK phosphorylation and IL-8 and GM-CSF production by human bronchial epithelial cells. Am J Physiol Lung Cell Mol Physiol 290 : L75-85, 2006
PubMed
3) Shinkai M, Rubin BK : Macrolides and airway inflammation in children. Paediatr Respir Rev 6 : 227-35, 2005
PubMed
4) Friedlander AL, Albert RK : Chronic macrolide therapy in inflammatory airways diseases. Chest 138 : 1202-12, 2010
PubMed
5) Nakata K, Taguchi Y, Kudoh S : Therapeutic guidelines for DPB (in Japanese). Annual Report on the study of diffuse lung disease in 1999. Tokyo : Ministry of Health and Welfare of Japan. p.111, 2000
 
6) Albrich WC, Monnet DL, Harbarth S : Antibiotic selection pressure and resistance in Streptococcus pneumoniae and Streptococcus pyogenes. Emerg Infect Dis 10 : 514-7, 2004
PubMed
7) Linares J, Ardanuy C, Pallares R, et al : Changes in antimicrobial resistance, serotypes and genotypes in Streptococcus pneumoniae over a 30-year period. Clin Microbiol Infect 16 : 402-10, 2010
 
8) Farrell DJ, Morrissey I, Bakker S, et al : Molecular characterization of macrolide resistance mechanisms among Streptococcus pneumoniae and Streptococcus pyogenes isolated from the PROTEKT 1999-2000 study. J Antimicrob Chemother 50 Suppl S1 : 39-47, 2002
 
9) Itoh Z, Nakaya M, Suzuki T, et al : Erythromycin mimics exogenous motilin in gastrointestinal contractile activity in the dog. Am J Physiol 247 (6 Pt 1) : G688-94, 1984
 
10) Suzuki T, Yanai M, Yamaya M, et al : Erythromycin and common cold in COPD. Chest 120 : 730-3, 2001
PubMed
11) Yamaya M, Azuma A, Tanaka H, et al : Inhibitory effects of macrolide antibiotics on exacerbations and hospitalization in chronic obstructive pulmonary disease in Japan : a retrospective multicenter analysis. J Am Geriatr Soc 56 : 1358-60, 2008
PubMed
12) Albert RK, Connett J, Bailey WC, et al : Azithromycin for prevention of exacerbations of COPD. N Engl J Med 365 : 689-98, 2011
PubMed
13) Herath SC, Poole P : Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD). Cochrane Database Syst Rev. 2013 (11) : CD009764.
PubMed
14) Wedzicha JA, Calverley PMA, Albert RK, et al : Prevention of COPD exacerbations : a European Respiratory Society/American Thoracic Society guideline. Eur Respir J 50 : pii1602265, 2017
PubMed
15) Miravitlles M : What was the impact of the Spanish COPD guidelines (GesEPOC) and how can they be improved? Arch Bronconeumol 52 : 1-2, 2016
PubMed
16) Amayasu H, Yoshida S, Ebana S, et al : Clarithromycin suppresses bronchial hyperresponsiveness associated with eosinophilic inflammation in patients with asthma. Ann Allergy Asthma Immunol 84 : 594-8, 2000
PubMed
17) Gotfried MH, Jung R, Messick CR, et al : Effects of six-week clarithromycin therapy in corticosteroiddependent asthma : A randomized, double-blind, placebo-controlled pilot study. Curr Ther Res Clin Exp 65 : 1-12, 2004
PubMed
18) Beuther DA, Martin RJ : Antibiotics in asthma. Curr Allergy Asthma Rep 4 (2) : 132-8, 2004
PubMed
19) Black PN, Scicchitano R, Jenkins CR, et al : Serological evidence of infection with Chlamydia pneumoniae is related to the severity of asthma. Eur Respir J 15 : 254-9, 2000
 
20) Kraft M, Cassell GH, Pak J, et al : Mycoplasma pneumoniae and Chlamydia pneumoniae in asthma : effect of clarithromycin. Chest 121 : 1782-8, 2002
PubMed
21) Brusselle GG, Vanderstichele C, Jordens P, et al : Azithromycin for prevention of exacerbations in severe asthma (AZISAST) : a multicentre randomised double-blind placebo-controlled trial. Thorax 68 : 322-9, 2013
PubMed
22) Gibson PG, Yang IA, Upham JW, et al : Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES) : a randomised, double-blind, placebocontrolled trial. Lancet 390 : 659-68, 2017
PubMed
23) Johnston SL, Szigeti M, Cross M, et al : A randomised, double-blind, placebo-controlled study to evaluate the efficacy of oral azithromycin as a supplement to standard care for adult patients with acute exacerbations of asthma (the AZALEA trial). Efficacy and Mechanism Evaluation. Southampton (UK) 2016.
 
24) Richeldi L, Ferrara G, Fabbri LM, et al : Macrolides for chronic asthma. Cochrane Database Syst Rev. 2002 (1) : CD002997.
PubMed
25) Reiter J, Demirel N, Mendy A, et al : Macrolides for the long-term management of asthma--a metaanalysis of randomized clinical trials. Allergy 68 : 1040-9, 2013
 
26) Wong EH, Porter JD, Edwards MR, et al : The role of macrolides in asthma : current evidence and future directions. Lancet Respir Med 2 : 657-70, 2014
PubMed
27) Rollins DR, Good JT, Jr., Martin RJ : The role of atypical infections and macrolide therapy in patients with asthma. J Allergy Clin Immunol Pract 2 : 511-7, 2014
PubMed
P.109 掲載の参考文献
1) 日本咳嗽研究会, アトピー咳嗽研究会 : 慢性咳嗽の診断と治療に関する指針. 2005年度版, 前田書店, 2006
 
2) Fujimura M : Frequency of persistent cough and trends in seeking medical care and treatment-results of an internet survey. Allergol Int 61 : 573-81, 2012
PubMed
3) Kohno S, Okada K, Kadota J, et al : The Japanese Respiratory Society guidelines for management of cough. second edition, in Japanese, 2012
 
4) Fujimura M, Ogawa H, Nishizawa Y, et al : Comparison of atopic cough with cough variant asthma : is atopic cough a precursor of asthma? Thorax 58 : 14-8, 2003
PubMed
5) 藤村政樹 : 咳喘息の病態・診断・治療. 臨床病理 62 : 464-70, 2012
 
6) 藤村政樹 (編) : 慢性咳嗽を診る 改訂版-症例から学ぶ-. 医薬ジャーナル社, 2010
 
7) 新実彰男 : 慢性咳嗽の実態と診断の進め方. 日本小児科学会雑誌 111 : 1535-44, 2007
 
8) Kita T, Fujimura M, Ogawa H, et al : Antitussive effects of the leukotriene receptor antagonist montelukast in patients with cough variant asthma and atopic cough. Allergol Int 59 : 185-92, 2010
PubMed

IV章 間質性肺炎

P.117 掲載の参考文献
1) Raghu G, Rochwerg B, Zhang Y, et al : An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline : Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline. Am J Respir Crit Care Med 192 : e3-19, 2015
 
2) 厚生労働科学研究費補助金難治性疾患政策研究事業「びまん性肺疾患に関する調査研究」班 (特発性肺線維症の治療ガイドライン作成委員会編) : 特発性肺線維症の治療ガイドライン 2017. 南江堂, 2017
 
3) King TE Jr, Bradford WZ, Castro-Bernardini S, et al : A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 370 : 2083-92. 2014
PubMed
4) Richeldi L, du Bois RM, Raghu G, et al : Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 370 : 2071-82. 2014
PubMed
5) Ogura T, Azuma A, Inoue Y, et al : All-case post-marketing surveillance of 1371 patients treated with pirfenidone for idiopathic pulmonary fibrosis. Respir Investig 53 : 232-41. 2015
PubMed
P.122 掲載の参考文献
1) Natsuizaka M, Chiba H, Kuronuma K. et al : Epidemiologic survey of Japanese patients with idiopathic pulmonary fibrosis and investigation of ethnic differences. Am J Respir Crit Care Med 190 : 773-9, 2014
PubMed
2) Albera C, Costabel U, Fagan EA, et al : Efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis with more preserved lung function. Eur Respir J 48 : 843-51, 2016
PubMed
3) Kolb M, Richeldi L, Behr J, et al : Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume. Thorax 72 : 340-6, 2017
PubMed
4) Costabel U, Inoue Y, Richeldi L, et al : Efficacy of nintedanib in idiopathic pulmonary fibrosis across prespecified subgroups in INPULSIS. Am J Respir Crit Care Med 193 : 178-85, 2016
PubMed
5) Nishiyama O, Taniguchi H, Kondoh Y, et al : A simple assessment of dyspnoea as a prognostic indicator in idiopathic pulmonary fibrosis. Eur Respir J 36 : 1067-72, 2010
PubMed
6) Zappala CJ, Latsi PI, Nicholson AG, et al : Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis. Eur Respir J 35 : 830-6, 2010
PubMed
7) Yamauchi H, Bando M, Baba T, et al : Clinical course and changes in high-resolution computed tomography findings in patients with idiopathic pulmonary fibrosis without honeycombing. PLoS One 11 : e0166168, 2016
PubMed
P.130 掲載の参考文献
1) Kreuter M, Walscher J, Behr J : Antifibrotic drugs as treatment of nonidiopathic pulmonary fibrosis interstitial pneumonias : the time is now (?). Curr Opin Pulm Med 23 : 418-25, 2017
PubMed
2) Taniguchi H, Kondoh Y, Ebina M, et al : The clinical significance of 5% change in vital capacity in patients with idiopathic pulmonary fibrosis : extended analysis of the pirfenidone trial. Respir Res 12 : 93, 2011
PubMed
3) Buendia-Roldan I, Mejia M, Barreto-Rodriguez O, et al : Pirfenidone shows some beneficial effect in patients with chronic hypersensitivity pneumonitis. Am J Respir Crit Care Med 191 : A4394, 2015
 
4) Khanna D, Albera C, Fischer A, et al : An Open-label, Phase II Study of the Safety and Tolerability of Pirfenidone in Patients with Scleroderma-associated Interstitial Lung Disease : the LOTUSS Trial. J Rheumatol 43 : 1672-9, 2016
 
5) Miura Y, Saito T, Fujita K, et al : Clinical experience with pirfenidone in five patients with scleroderma-related interstitial lung disease. Sarcoidosis Vasc Diffuse Lung Dis 31 : 235-8, 2014
PubMed
6) Bournia VK, Vlachoyiannopoulos PG, Selmi C, et al : Recent advances in the treatment of systemic sclerosis. Clin Rev Allergy Immunol 36 : 176-200, 2009
PubMed
7) Lehtonen S T, Veijola A, Karvonen H, et al : Pirfenidone and nintedanib modulate properties of fibroblasts and myofibroblasts in idiopathic pulmonary fibrosis. Respir Res 17 : 14, 2016
PubMed
8) Okuda R, Hagiwara E, Baba T, et al : Safety and efficacy of pirfenidone in idiopathic pulmonary fibrosis in clinical practice. Respir Med 107 : 1431-7, 2013
PubMed
P.135 掲載の参考文献
1) Azuma A, Nukiwa T, Tsuboi E, et al : Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 171 : 1040-7, 2005
PubMed
2) Taniguchi H, Ebina M, Kondoh Y, et al : Pirfenidone in idiopathic pulmonary fibrosis. Eur Respir J 35 : 821-9, 2010
PubMed
3) Noble PW, Albera C, Bradford WZ, et al : Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY) : two randomised trials. Lancet 377 : 1760-9, 2011
PubMed
4) King TE Jr, Bradford WZ, Castro-Bernardini S, et al : A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 370 : 2083-92, 2014
PubMed
5) Aravena C, Labarca G, Venegas C, et al : Pirfenidone for idiopathic pulmonary fibrosis : a systematic review and meta-analysis. PLoS One 10 : e0136160, 2015
PubMed
6) Ogura T, Azuma A, Inoue Y, et al : All-case post-marketing surveillance of 1371 patients treated with pirfenidone for idiopathic pulmonary fibrosis. Respir Investig 53 : 232-41, 2015
PubMed
7) Okuda R, Hagiwara E, Baba T, et al : Safety and efficacy of pirfenidone in idiopathic pulmonary fibrosis in clinical practice. Respiratory Medicine 107 : 1431-7, 2013
PubMed
8) Rubino CM, Bhavnani SM, Ambrose PG, et al : Effect of food and antacids on the pharmacokinetics of pirfenidone in older healthy adults. Pulm Pharmacol Ther 22 : 279-85, 2009
PubMed
9) Itoh T, Koyabu K, Morimoto A, et al : Ameliorative effects of mosapride or rikkunshi-to on the suppression of gastrointestinal motility by pirfenidone in rats. 薬理と治療 40 : 405-11, 2012
 
10) Arai T, Inoue Y, Sasaki Y, et al : Predictors of the clinical effects of pirfenidone on idiopathic pulmonary fibrosis. Respir Investig 52 : 136-43, 2014
PubMed
11) Uehara M, Enomoto N, Oyama Y, et al : Body size-adjusted dose analysis of pirfenidone in patients with interstitial pneumonia. Respirology, 2017 [Epub ahead of print]
 
12) Seto Y, Inoue R, Kato M, et al : Photosafety assessments on pirfenidone : photochemical, photobiological, and pharmacokinetic characterization. J Photochem Photobiol B 120 : 44-51, 2013
PubMed
13) Richeldi L, Costabel U, Selman M, et al : Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med 365 : 1079-87, 2011
PubMed
14) Richeldi L, du Bois RM, Raghu G, et al : Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 370 : 2071-82, 2014
PubMed
15) Bonella F, Kreuter M, Hagmeyer L, et al : Insights from the German Compassionate Use Program of Nintedanib for the Treatment of Idiopathic Pulmonary Fibrosis. Respiration 92 : 98-106, 2016
PubMed
16) Allinger A, Kaul M, Conoscenti CS, et al : Safety and Tolerability of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis (IPF) : One-Year Data from Post-Marketing Surveillance in the United States. A103 IPF : MORE ABOUT THERAPY AND OUTCOMES, p. A2692-A2692.
 
17) Crestani B, Quaresma M, Kaye M, et al : Long-term treatment with nintedanib in patients with IPF : An update from INPULSIS R-ON. Eur Respir J 48 : 48 (Suppl 60) OA4960, 2016
 
18) Ikeda S, Sekine A, Baba T, et al : Hepatotoxicity of nintedanib in patients with idiopathic pulmonary fibrosis : A single-center experience. Respir Investig 55 : 51-4, 2017
PubMed
19) Marzin K, Kretschmar G, Luedtke D, et al : Pharmacokinetics of nintedanib in subjects with hepatic impairment. J Clin Pharmacol 2017 [Epub ahead of print]
 
P.141 掲載の参考文献
1) 日本呼吸器学会びまん性肺疾患診断・治療ガイドライン作成委員会 : 特発性間質性肺炎 診断と治療の手引き改訂第3版, 南江堂, 2016.
 
2) Raghu G, Collard HR, Egan JJ, et al : An official ATS/ERS/JRS/ALAT statement : Idiopathic pulmonary fibrosis : Evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 183 : 788-824, 2011
PubMed
3) Raghu G, Rochwerg B, Zhang Y, et al : An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline : Treatment of idiopathic pulmonary fibrosis. An Update of the 2011 Clinical Practice Guideline. Am J Respir Crit Care Med 192 : e3-e19, 2015
 
4) 厚生労働科学研究費補助金難治性疾患政策研究事業「びまん性肺疾患に関する調査研究」班特発性肺線維症の治療ガイドライン作成委員会 (編), 特発性肺線維症の治療ガイドライン 2017. 日本呼吸器学会 (監修), 東京 : 南江堂, 2017.
 
5) Bando M, Sugiyama Y, Azuma A, et al : A prospective survey of idiopathic interstitial pneumonias in a web registry in Japan. Respir Investig 53 : 51-9, 2015
 
6) Miyazaki Y, Azuma A, Inase N, et al : Cyclosporine A combined with low-dose corticosteroid treatment in patients with idiopathic pulmonary fibrosis. Respir Investig 53 : 288-95, 2015
PubMed
7) Richeldi L, du Bois RM, Raghu G, et al : Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 370 : 2071-82, 2014
PubMed
P.146 掲載の参考文献
1) Demedts M, Behr J, Buhl R, et al : High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 353 : 2229-42, 2005
PubMed
2) Raghu G, Anstrom KJ, King TE Jr, et al : Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med 366 : 1968-77, 2012
 
3) Martinez FJ, de Andrade JA, Anstrom KJ, et al : Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med 370 : 2093-101, 2014
PubMed
4) Oldham JM, Ma SF, Martinez FJ, et al : TOLLIP, MUC5B, and the response to N-acetylcysteine among individuals with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 192 : 1475-82, 2015
 
5) Tomioka H, Kuwata Y, Imanaka K, et al : A pilot study of aerosolized N-acetylcysteine for idiopathic pulmonary fibrosis. Respirology 10 : 449-55, 2005
PubMed
6) Homma S, Azuma A, Taniguchi H, et al : Efficacy of inhaled N-acetylcysteine monotherapy in patients with early stage idiopathic pulmonary fibrosis. Respirology 17 : 467-77, 2012
PubMed
7) Felton VM, Borok Z, Willis BC : N-acetylcystein inhibits alveolar epithelial-mesenchymal transition. Am J Physiol Lung Cell Mol Physiol 297 : L805-12, 2009
PubMed
8) Muramatsu Y, Sugino K, Ishida F, et al : Effect of inhaled N-acetylcysteine monotherapy on lung function and redox balance in idiopathic pulmonary fibrosis. Respir Investig 54 : 170-8, 2016
PubMed
9) 杉野圭史, 石田文昭, 村松陽子ほか : 特発性肺線維症におけるNAC単独吸入療法の効果とレドックス制御. 厚生労働科学研究「特発性肺線維症の予後改善を目指したサイクロスポリン+ステロイド療法ならびにNアセチルシステイン吸入療法に関する臨床研究」班平成20年度研究会報告書, p.13-18, 2009
 
P.151 掲載の参考文献
1) 厚生労働科学研究費補助金難治性疾患政策研究事業「びまん性肺疾患に関する調査研究」班 特発性肺線維症の治療ガイドライン作成委員会 : 特発性肺線維症の治療ガイドライン 2017, 南江堂, p.23-32, 2017
 
2) Tsushima K, Yamaguchi K, Kono Y, et al : Thrombomodulin for acute exacerbations of idiopathic pulmonary fibrosis : a proof of concept study. Pulm Pharmacol Ther 29 : 233-40, 2014
PubMed
3) Isshiki T, Sakamoto S, Kinoshita A, et al : Recombinant human soluble thrombomodulin treatment for acute exacerbation of idiopathic pulmonary fibrosis : a retrospective study. Respiration 89 : 201-7, 2015
PubMed
4) Kataoka K, Taniguchi H, Kondoh Y, et al : Recombinant human thrombomodulin in acute exacerbation of idiopathic pulmonary fibrosis. Chest 148 : 436-43, 2015
PubMed
5) Abe M, Tsushima K, Matsumura T, et al : Efficacy of thrombomodulin for acute exacerbation of idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia : a nonrandomized prospective study. Drug Des Devel Ther 9 : 5755-62. Collection 2015
 
6) Hayakawa S, Matsuzawa Y, Irie T, et al : Efficacy of recombinant human soluble thrombomodulin for the treatment of acute exacerbation of idiopathic pulmonary fibrosis : a single arm, non-randomized prospective clinical trial. Multidiscip Respir Med 11 : 38. eCollection 2016
 
P.156 掲載の参考文献
1) Mathai SC, Danoff SK : Management of interstitial lung disease associated with connective tissue disease. BMJ 352 : h6819, 2016
PubMed
2) Alba MA, Flores-Suarez LF, Henderson AG, et al : Interstitial lung disease in ANCA vasculitis. Autoimmun Rev 16 : 722-9, 2017
PubMed
3) Kelley's Textbook of Rheumatology Ninth Edition. Saunders, 2012
 
4) Marigliano B, Soriano A, Margiotta D, et al : Lung involvement in connective tissue diseases : A comprehensive review and a focus on rheumatoid arthritis. Autoimmun Rev 12 : 1076-84, 2013
 
5) 厚生労働省科学研究費補助金 難治性疾患政策研究事業 自己免疫疾患に対する調査研究班 多発性筋炎皮膚筋炎分科会 : 多発性筋炎・皮膚筋炎診療ガイドライン. 診断と治療社, 2015
 
6) Tashkin DP, Roth MD, Clements PJ, et al : Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related lung disease (SLS II) : a randomized controlled, double-blind, parallel group trial. Lancet Respir Med 4 : 708-19, 2016
 

V章 肺癌

P.163 掲載の参考文献
1) 日本肺癌学会編 : 肺癌診療ガイドライン 2016年版.
 
2) Rotow J, Bivona TG : Understanding and targeting resistance mechanisms in NSCLC. Nat Rev Cancer 17 : 637-58, 2017
PubMed
3) Kudoh S, Kato H, Nishiwaki Y, et al : Interstitial lung disease in Japanese patients with lung cancer : a cohort and nested case-control study. Am J Respir Crit Care Med 177 : 1348-57, 2008
PubMed
4) Benson AB 3rd, Ajani JA, Catalano RB : Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol 22 : 2918-26, 2004
PubMed
P.168 掲載の参考文献
1) Kuiper JL, Heideman DA, Wurdinger T, et al : Rationale and study design of the IRENE-trial (NVALT-16) : a phase II trial to evaluate iressa rechallenge in advanced NSCLC patients with an activating EGFR mutation who responded to an EGFR-TKI used as first-line or previous treatment. Clin Lung Cancer 16 : 60-6, 2015
 
2) Nishino K, Imamura F, Morita S, et al : A retrospective analysis of 335 Japanese lung cancer patients who responded to initial gefitinib treatment. Lung Cancer 82 : 299-304, 2013
PubMed
3) Kaira K, Naito T, Takahashi T, et al : Pooled analysis of the reports of erlotinib after failure of gefitinib for non-small cell lung cancer. Lung Cancer 68 : 99-104, 2010
PubMed
4) Zhou C, Yao LD : Strategies to improve outcomes of patients with EGRF-mutant non-small cell lung cancer : Review of the literature. J Thorac Oncol 11 : 174-86, 2016
PubMed
5) Kijima T, Shimizu T, Kawase I, et al : Safe and successful treatment with erlotinib after gefitinibinduced hepatotoxicity : difference in metabolism as a possible mechanism. J Clin Oncol 29 : e588-e590, 2011
PubMed
P.173 掲載の参考文献
1) Soda M, Choi YL, Enomoto M, et al : Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448 : 561-6, 2007
PubMed
2) Kwak EL, Bang YJ, Camidge DR, et al : Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363 : 1693-703, 2010
PubMed
3) Solomon BJ, Mok T, Kim DW, et al : First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 371 : 2167-77, 2014
PubMed
4) Shaw AT, Kim DW, Nakagawa K, et al : Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 368 : 2385-94, 2013
PubMed
5) Seto T, Kiura K, Nishino M, et al : CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study) : a single-arm, open-label, phase 1-2 study. Lancet Oncol 14 : 590-8, 2013
 
6) Friboulet L, Li N, Katayama R, et al : The ALK inhibitor ceritinib overcomes crizotinib resistance in non-small cell lung cancer. Cancer Discov 4 : 662-73, 2014
PubMed
7) Shaw AT, Engelman JA : Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med 370 : 1189-97, 2014
PubMed
8) Nishio M, Murakami H, Horiike A, et al : Phase I study of ceritinib (LDK378) in Japanese patients with advanced, anaplastic lymphoma kinase-rearranged non-small-cell lung cancer or other tumors. J Thorac Oncol 10 : 1058-66, 2015
PubMed
9) Soria JC, Tan DSW, Chiari R, et al : First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4) : a randomised, open-label, phase 3 study. Lancet 389 : 917-29, 2017
PubMed
10) Shaw AT, Kim TM, Chino L, et al : Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5) : a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 18 : 874-86, 2017
 
11) Choi YL, Soda M, Yamashita Y, et al : EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med 363 : 1734-9, 2010
PubMed
12) Katayama R, Shaw AT, Khan TM, et al : Mechanisms of acquired crizotinib resistance in ALKrearranged lung cancers. Sci Transl Med 4 : 120ra17, 2012
PubMed
13) Katayama R, Sakashita T, Yanagitani N, et al : P-glycoprotein mediates ceritinib resistance in anaplastic lymphoma kinase-rearranged non-small cell lung cancer. EBioMedicine 3 : 54-66, 2016
PubMed
14) Gainor JF, Dardaei L, Yoda S, et al : Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer. Cancer Discov 6 : 1118-33, 2016
PubMed
15) Shaw AT, Gandhi L, Gadgeel S, et al : Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer : a single-group, multicentre, phase 2 trial. Lancet Oncol 17 : 234-42, 2016
PubMed
16) Ou SH, Ahn JS, De Petris L, et al : Alectinib in crizotinib-refractory ALK-rearranged non-small-cell lung cancer : A phase II global study. J Clin Oncol 34 : 661-8, 2016
PubMed
17) Kogita A, Togashi Y, Hayashi H, et al : Activated MET acts as a salvage signal after treatment with alectinib, a selective ALK inhibitor, in ALK-positive non-small cell lung cancer. Int J Oncol 46 : 1025-30, 2015
PubMed
P.181 掲載の参考文献
1) Garon EB, Rizvi NA, Hui R, et al : Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 372 : 2018-28, 2015
PubMed
2) Herbst RS, Baas P, Kim DW, et al. : Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010) : a randomised controlled trial. Lancet Oncol 387 : 1540-50, 2016
 
3) Reck M, Rodriguez-Abreu D, Robinson AG, et al. : Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 375 : 1823-33, 2016
PubMed
4) Brahmer JR, Rodriguez-Abreu D, Robinson AG, et al. : Progression after the next line of therapy (PFS2) and updated OS among patients with advanced NSCLC and PD-L1 TPS ≧50 % enrolled in KEYNOTE-024. ASCO Annual meeting abstract #9000, 2017.
 
5) Rangachari D, VanderLaan PA, Shea M, et al. : Correlation between classic driver oncogene mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 ≧50% expression in lung adenocarcinoma. J Thorac Oncol 12 : 878-83, 2017
 
P.186 掲載の参考文献
1) Brahmer J, Reckamp KL, Baas P, et al : Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373 : 123-35, 2015
PubMed
2) Borghaei H, Paz-Ares L, Horn L, et al : Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373 : 1627-39, 2015
PubMed
3) Herbst RS, Baas P, Kim DW, et al : Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010) : a randomised controlled trial. Lancet 387 : 1540-50, 2016
PubMed
4) Rittmeyer A, Barlesi F, Waterkamp D, et al : Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK) : a phase 3, open-label, multicentre randomised controlled trial. Lancet 389 : 255-65, 2017
 
5) Garon EB, Ciuleanu TE, Arrieta O, et al : Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinumbased therapy (REVEL) : a multicentre, double-blind, randomised phase 3 trial. Lancet 384 : 665-73, 2014
 
P.191 掲載の参考文献
1) Brahmer J, Reckamp KL, Baas P, et al : Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 373 : 123-35, 2015
PubMed
2) Borghaei H, Paz-Ares L, Horn L, et al : Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 373 : 1627-39, 2015
PubMed
3) Horn L, Spigel DR, Vokes EE, et al : Nivolumab versus docetaxel in previously treated patients with advanced non-small-cell lung cancer : two-year outcomes from two randomized, open-label, phase III trials (CheckMate 017 and CheckMate 057). J Clin Oncol [Epub ahead of print] , 2017
 
4) Garon EB, Ciuleanu TE, Arrieta O, et al : Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL) : a multicenter, double-blind, randomized phase 3 trial. Lancet 384 : 665-73, 2014
 
5) Nokihara H, Lu S, Mok TSK, et al : Randomized controlled trial of S-1 versus docetaxel in patients with non-small-cell lung cancer previously treated with platinukb-based chemotherapy (East asia S-1 trial in lung cancer). Ann Oncol 28 : 2698-706, 2017
PubMed
6) 日本肺癌学会 : EBMの手法による肺癌診療ガイドライン2016年版 第4版. 金原出版, 2016
 
P.195 掲載の参考文献
1) Shaw AT, Solomon BJ : Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med 372 : 683, 2015
PubMed
2) Mazieres J, Zalcman G, Crino L, et al : Crizotinib therapy for advanced lung adenocarcinoma and a ROS1 rearrangement : results from the EUROS1 cohort. J Clin Oncol 33 : 992, 2015
 
3) Goto K, Yang JC, Kim DW, et al : Phase II study of crizotinib in east Asian patients (pts) with ROS1-positive advanced non-small cell lung cancer (NSCLC). J Clin Oncol 34, 2016 (suppl ; abstr 9022)
 
4) Lim SM, Kim HR, Lee JS, et al : Open-label, multicenter, phase II study of ceritinib in patients with non-small-cell lung cancer harboring ROS1 rearrangement. J Clin Oncol 35 : 2613, 2017
PubMed
5) Shaw AT, Felip E, Bauer TM, et al : Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement : an international, multicentre, open-label, single-arm first-in-man phase 1 trial. Lancet Oncol 18 : 1590, 2017
 
P.200 掲載の参考文献
1) Ellis LM, Hicklin DJ : VEGF-targeted therapy : mechanisms of anti-tumour activity. Nat Rev Cancer 8 : 579-91, 2008
PubMed
2) Soria JC, Mauguen A, Reck M, et al : Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer. Ann Oncol 24 : 20-30, 2013
PubMed
3) Garon EB, Ciuleanu TE, Arrieta O, et al : Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinumbased therapy (REVEL) : a multicentre, double-blind, randomised phase 3 trial. Lancet 384 : 665-73, 2014
 
4) Yoh K, Hosomi Y, Kasahara K, et al : A randomized, double-blind, phase II study of ramucirumab plus docetaxel vs placebo plus docetaxel in Japanese patients with stage IV non-small cell lung cancer after disease progression on platinum-based therapy. Lung Cancer 99 : 186-93, 2016
PubMed
5) Seto T, Kato T, Nishio M, et al : Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567) : an open-label, randomised, multicentre, phase 2 study. Lancet Oncol 15 : 1236-44, 2014
 
P.206 掲載の参考文献
1) Iuchi T, Shingyoji M, Itakura M, et al : Frequency of brain metastases in non-small-cell lung cancer, and their association with epidermal growth factor receptor mutations. Int J Clin Oncol 20 : 674-79, 2015
PubMed
2) Wu YL, Zhou C, Cheng Y, et al : Erlotinib as second-line treatment in patients with advanced non-small-cell lung cancer and asymptomatic brain metastases : a phase II study (CTONG-0803). Ann Oncol 24 : 993-9, 2013
 
3) Togashi Y, Masago K, Masuda S, et al : Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer. Cancer Chemother Pharmacol 70 : 399-405, 2012
PubMed
4) Lee E, Keam B, Kim DW, et al : Erlotinib versus gefitinib for control of leptomeningeal carcinomatosis in non-small-cell lung cancer. J Thorac Oncol 8 : 1069-74, 2013
PubMed
5) Park K, Tan EH, O'Byrne K, et al : Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7) : a phase 2B, open-label, randomised controlled trial. Lancet Oncol 17 : 577-89, 2016
PubMed
6) Mok TS, Wu YL, Ahn MJ, et al : Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer. N Engl J Med 376 : 629-40, 2017
 
7) Costa DB, Shaw AT, Ou SH, et al : Clinical experience with crizotinib in patients with advanced ALKrearranged non-small-cell lung cancer and brain metastases. J Clin Oncol 33 : 1881-8, 2015
PubMed
8) Kodama T, Hasegawa M, Takanashi K, et al : Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases. Cancer Chemother Pharmacol 74 : 1023-8, 2014
PubMed
9) Gadgeel SM, Gandhi L, Riely GJ, et al : Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG) : results from the dose-finding portion of a phase 1/2 study. Lancet Oncol 15 : 1119-28, 2014
PubMed
10) Hida T, Nokihara H, Kondo M, et al : Alectinib versus crizotinib in patients with ALK-positive non small-cell lung cancer (J-ALEX) : an open-label, randomised phase 3 trial. Lancet 390 : 29-39, 2017
PubMed
11) Shaw AT, Kim TM, Crino L, et al : Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5) : a randomised, controlled, open-label, phase 3 trial. Lancet Oncol 18 : 874-86, 2017
PubMed
12) Shaw AT, Felip E, Bauer TM, et al : Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement : an international, multicentre, open-label, single-arm first-in-man phase 1 trial. Lancet Oncol 18 : 1590-9, 2017
 
13) Shaw AT, Ou SH, Bang YJ, et al : Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med 371 : 1963-71, 2014
PubMed
14) Barlesi F, Gervais R, Lena H, et al : Pemetrexed and cisplatin as first-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) with asymptomatic inoperable brain metastases : a multicenter phase II trial (GFPC 07-01). Ann Oncol 22 : 2466-70, 2011
PubMed
15) Ortuzar W, Hanna N, Pennella E, et al : Brain metastases as the primary site of relapse in two randomized phase III pemetrexed trials in advanced non-small-cell lung cancer. Clin Lung Cancer 13 : 24-30, 2012
PubMed
16) Socinski MA, Langer CJ, Huang JE, et al : Safety of bevacizumab in patients with non-small-cell lung cancer and brain metastases. J Clin Oncol 27 : 5255-61, 2009
PubMed
17) Besse B, Le Moulec S, Mazieres J, et al : Bevacizumab in Patients with Nonsquamous Non-Small Cell Lung Cancer and Asymptomatic, Untreated Brain Metastases (BRAIN) : A nonrandomized, phase II study. Clin Cancer Res 21 : 1896-903, 2015
 
18) Arnold D, Fuchs CS, Tabernero J, et al : Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab. Ann Oncol 28 : 2932-42, 2017
PubMed
19) Magnuson WJ, Lester-Coll NH, Wu AJ, et al : Management of brain metastases in tyrosine kinase inhibitor-naive epidermal growth factor receptor-mutant non-small-cell lung cancer : a retrospective multi-institutional analysis. J Clin Oncol 35 : 1070-7, 2017
PubMed
P.211 掲載の参考文献
1) 間質性肺炎合併肺癌に関するステートメント, 日本呼吸器学会腫瘍学術部会・びまん性肺疾患学術部会. 2017年10月20日発行
 
2) Kenmotsu H, Naito T, Kimura M, et al : The risk of cytotoxic chemotherapy-related exacerbation of interstitial lung disease with lung cancer. J Thorac Oncol 6 : 1242-6, 2011
PubMed
3) Enomoto Y, Inui N, Kato T, et al : Low forced vital capacity predicts cytotoxic chemotherapy-associated acute exacerbation of interstitial lung disease in patients with lung cancer. Lung Cancer 96 : 63-7, 2016
PubMed
4) Minegishi Y, Sudoh J, Kuribayasi H, et al : The safety and efficacy of weekly paclitaxel in combination with carboplatin for advanced non-small cell lung cancer with idiopathic interstitial pneumonias. Lung Cancer 71 : 70-4, 2011
PubMed
5) Sekine A, Satoh H, Baba T, et al : Safety and efficacy of S-1 in combination with carboplatin in non-small cell lung cancer patients with interstitial lung disease : a pilot study. Cancer Chemother Pharmacol 77 : 1245-52, 2016
PubMed
6) Shimizu R, Fujimoto D, Kato R, et al : The safety and efficacy of paclitaxel and carboplatin with or without bevacizumab for treating patients with advanced nonsquamous non-small cell lung cancer with interstitial lung disease. Cancer Chemother Pharmacol 74 : 1159-66, 2014
 
7) Kenmotsu H, Naito T, Mori K, et al : Effect of platinum-based chemotherapy for non-small cell lung cancer patients with interstitial lung disease. Cancer Chemother Pharmacol 75 : 521-6, 2015
PubMed
8) Kato M, Shukuya T, Takahashi F, et al : Pemetrexed for advanced non-small cell lung cancer patients with interstitial lung disease. BMC Cancer 14 : 508, 2014
PubMed
9) Otsubo K, Kishimoto J, Kenmotsu H, et al : Treatment rationale and design for J-SONIC : A randomized study of carboplatin plus nab-paclitaxel with or without nintedanib for advanced non-small-cell lung cancer with idiopathic pulmonary fibrosis. Clin Lung Cancer 19 : e5-e9, 2017
PubMed
10) Masuda N, Fukuoka M, Kusunoki Y, et al : CPT-11 : a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 10 : 1225-9, 1992
PubMed
11) Minegishi Y, Kuribayashi H, Kitamura K, et al : The feasibility study of Carboplatin plus Etoposide for advanced small cell lung cancer with idiopathic interstitial pneumonias. J Thorac Oncol 6 : 801-7, 2011
PubMed
12) Yoshida T, Yoh K, Goto K, et al : Safety and efficacy of platinum agents plus etoposide for patients with small cell lung cancer with interstitial lung disease. Anticancer Res 33 : 1175-9, 2013
PubMed
13) びまん性肺疾患に関する調査研究班, 平成21年度研究報告書 : 105-107
 
14) Enomoto Y, Inui N, Imokawa S, et al : Safety of topotecan monotherapy for relapsed small cell lung cancer patients with pre-existing interstitial lung disease. Cancer Chemother Pharmacol 76 : 499-505, 2015
PubMed
P.214 掲載の参考文献
1) 日本癌治療学会編 : G-CSF適正使用ガイドライン2013年度版 Ver.2. p.52-5, 金原出版, 2013
 
2) Ohe Y, Ohashi Y, Kubota K, et al : Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer : Four-Arm Cooperative Study in Japan. Ann Oncol 18 : 317-23, 2007
PubMed
3) Yoh K, Hosomi Y, Kasahara K, et al : A randomized, double-blind, phase II study of ramucirumab plus docetaxel vs placebo plus docetaxel in Japanese patients with stage IV non-small cell lung cancer after disease progression on platinum-based therapy. Lung Cancer 99 : 186-93, 2016
PubMed
4) Hanna N, Bunn Jr P, Langer C, et al : Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol 24 : 2038-43, 2006
PubMed
5) Murakami H, Yamamoto N, Shibata T, et al : A single-arm confirmatory study of amrubicin therapy in patients with refractory small-cell lung cancer. Lung Cancer 84 : 67-72, 2014
 

VI章 肺感染症

P.222 掲載の参考文献
1) 日本呼吸器学会肺炎診療ガイドライン作成委員会 : 成人肺炎診療ガイドライン 2017. 日本呼吸器学会, 2017
 
2) Cunha BA : Antibiotic essentials. Royal Oak, MI ; Physicians Press, 2009
 
3) Yanagihara K, Watanabe A, Aoki N, et al : Nationwide surveillance of bacterial respiratory pathogens conducted by the surveillance committee of Japanese Society of Chemotherapy, the Japanese Association for Infectious Diseases, and the Japanese Society for Clinical Microbiology in 2012 : General view of the pathogens' antibacterial susceptibility. J Infect Chemother 23 : 587-97, 2017
PubMed
P.228 掲載の参考文献
1) Dellinger RP, Levy MM, American Thoracic Society, Infectious Diseases Society of America : Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 171 : 388-416, 2005
 
2) 日本呼吸器学会呼吸器感染症に関するガイドライン作成委員会 : 成人院内肺炎診療ガイドライン. 2008
 
3) 日本呼吸器学会 : 成人肺炎診療ガイドライン. 2017
 
4) Kalil AC : Executive Summary : Management of Adults with Hospital-acquired and Ventilator-associated Pneumonia : 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis 63 : 575-82, 2016
 
5) Seki M, Watanabe A, Mikasa K, et al : Revision of the Severity Rating and Classification of Hospital-acquired Pneumonia in the Japanese Respiratory Society Guidelines. Respirology 13 : 880-5, 2008
 
6) Dellinger RP, Levy MM, Carlet JM, et al : Surviving Sepsis Campaign : International guidelines for management of severe sepsis and septic shock 2012. Crit Care Med 41 : 580-637, 2013
 
7) 日本呼吸器学会 : 医療・介護関連肺炎診療ガイドライン. 2011
 
8) Kett DH, Cano E, Quartin AA, et al : Implementation of guidelines for management of possible multidrug-resistant pneumonia in intensive care : an observational, multicentre cohort study. Lancet Infect Dis 11 : 181-9, 2011
PubMed
9) Sakaguchi M, Shime N, Fujta N, et al : Current problems in the diagnosis and treatment of hospital-acquired methicillin-resistant Staphylococcus aureus pneumonia. J Anesth. 22 : 125-30, 2008
 
10) 日本化学療法学会 : Antimicrobial Stewardship ガイダンス. 2017
 
P.232 掲載の参考文献
1) Kawai Y, Miyashita N, Kudo M, et al : Nationwide surveillance of macrolide-resistant Mycoplasma pneumoniae infection in pediatric patients. Antimicrob Agents Chemother 57 : 4046-49, 2013
 
2) Miyashita N, Kawai Y, Akaike H, et al : Macrolide-resistant Mycoplasma pneumoniae in adolescents with community-acquired pneumonia. BMC Infect Dis 12 : 126, 2012
PubMed
3) 肺炎マイコプラズマ肺炎に対する治療指針策定委員会 : 肺炎マイコプラズマ肺炎に対する治療指針, p.1-48, 日本マイコプラズマ学会, 英語版 2016
 
4) Miyashita N, Akaike H, Teranishi H, et al : Macrolide-resistant Mycoplasma pneumoniae pneumonia in adolescents and adults : clinical findings, drug susceptibility and therapeutic efficacy. Antimicrob Agents Chemother 57 : 5181-5, 2013
PubMed
5) Miyashita N, Kawai Y, Inamura N, et al : Setting a standard for the initiation of steroid therapy in refractory or severe Mycoplasma pneumoniae pneumonia in adolescents and adults. J Infect Chemother 21 : 153-60, 2015
PubMed
P.236 掲載の参考文献
1) Meropol SB, Localio AR, Metlay JP : Risks and benefits associated with antibiotic use for acute respiratory infections : a cohort study. Ann Fam Med 11 : 165-72, 2013
PubMed
2) Fine AM, Nizet V, Mandol KD : Large-scale validation of the Centor and McIsaac scores to predict group A streptococcal pharyngitis. Arch Intern Med 172 : 847-52, 2012
 
3) Kenealy T, Arroll B : Antibiotics for the common cold and acute purulent rhinitis. Cochrane Database Syst Rev 2013 ; 6 : CD000247
PubMed
4) Harris AM, Hicks LA, Qaseem A : Appropriate antibiotic use for acute respiratory tract infection in adults : Advice for high-value care from the American College of Physicians and the Centers for Disease Control and Prevetion. Ann Intern Med 164 : 425-34, 2016
 
5) Vollenweider DJ, Jarrett H, Steurer-Stey CA, et al : Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2012 : 12 : CD010257
 
P.242 掲載の参考文献
1) 日本結核病学会非結核性抗酸菌症対策委員会, 日本呼吸器学会感染症・結核学術部会 : 肺非結核性抗酸菌症化学療法に関する見解-2012年改訂. 結核 87 : 83, 2012
Medical*Online
2) Griffith DE, Aksamit T, Brown-Elliot BA, et al : An official ATS/IDSA statement : diagnosis, treatment, and prevention of nontuberculous mycobacterial disease. Am J Respir Crit Care Med 175 : 367-416, 2007
 
3) 第85回日本結核病学会総会Pro & Con「非結核性抗酸菌症の治療-すべきか否か-」2010年5月 京都
 
P.247 掲載の参考文献
1) Guidelines for chemotherapy of pulmonary nontuberculous mycobacterial disease-2012 revised version. Kekkaku 88 : 29-32, 2013
PubMed
2) Griffith DE, Aksamit T, Brown-Elliott BA, et al : An official ATS/IDSA statement : diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 175 : 367-416, 2007
PubMed
3) Haworth CS, Banks J, Capstick T, et al : British Thoracic Society guidelines for the management of non-tuberculous mycobacterial pulmonary disease (NTM-PD). Thorax 72 (Suppl 2) : ii1-ii64, 2017
 
4) Wallace RJ, Jr., Brown-Elliott BA, McNulty S, et al : Macrolide/Azalide therapy for nodular/bronchiectatic mycobacterium avium complex lung disease. Chest 146 : 276-82, 2014
PubMed
5) Jeong BH, Jeon K, Park HY, et al : Intermittent antibiotic therapy for nodular bronchiectatic Mycobacterium avium complex lung disease. Am J Respir Crit Care Med 191 : 96-103, 2015
PubMed
6) Morimoto K, Iwai K, Uchimura K, et al : A steady increase in nontuberculous mycobacteriosis mortality and estimated prevalence in Japan. Ann Am Thorac Soc 11 : 1-8, 2014
PubMed
7) Morimoto K, Namkoong H, Hasegawa N, et al : Macrolide-resistant Mycobacterium avium complex lung disease : analysis of 102 consecutive cases. Annals of the American Thoracic Society 13 : 1904-11, 2016
PubMed
8) Polverino E, Goeminne PC, McDonnell MJ, et al : European Respiratory Society guidelines for the management of adult bronchiectasis. Eur Respir J : 50, 2017
PubMed
9) Morimoto K, Hasegawa N, Izumi K, et al : A laboratory-based analysis of nontuberculous mycobacterial lung disease in Japan from 2012 to 2013. Ann Am Thorac Soc 14 : 49-56, 2016
 
P.251 掲載の参考文献
1) Takeuchi T, Tatsuki Y, Nogami Y, et al : Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis 67 : 189-94, 2008
PubMed
2) 日本リウマチ学会 : 関節リウマチ (RA) に対するTNF 阻害薬使用ガイドライン (2017年3月21日改訂版) (http://www.ryumachi-jp.com/info/guideline_TNF.html) [accessed : 2017. 11. 30]
 
3) 徳田 均, 舘田一博, 渡辺 彰ほか : 生物学的製剤と呼吸器疾患・診療の手引き. 各論 2. 抗酸菌感染症. 生物学的製剤と呼吸器疾患・診療の手引き作成委員会. 日本呼吸器学会 (編), 克誠堂, p.49-58, 2014
 
4) Winthrop KL, Baxter R, Liu L, et al : Mycobacterial diseases and antitumor necrosis factor therapy in USA. Ann Rheum Dis 72 : 37-42, 2013
 
5) 日本結核病学会非結核性抗酸菌症対策委員会・日本呼吸器学会感染症・結核学術部会 : 肺非結核性抗酸菌症診断に関する指針. 結核 87 : 83-6, 2012
 
P.256 掲載の参考文献
1) 日本結核病学会治療委員会 : 「結核医療の基準」 の見直し-2014年. 結核 89 : 683-90, 2014
Medical*Online
2) ミコブチン医薬品インタビューフォーム : ファイザー社
 
3) Kawaguchi H, Naito T, Nakagawa S, et al : BB-K8, A new semisynthetic aminoglycoside antibiotic. J Antibiot 25 : 695-708, 1972
PubMed
4) 硫酸カナマイシン注1000 mg「明治」 インタビューフォーム
 
5) 日本結核病学会治療委員会・非結核性抗酸菌症対策委員会 : フルオロキノロン剤およびアミカシン硫酸塩の結核への使用について 日本結核病会ホームページ (https://www.kekkaku.gr.jp/commit/tiryou/201206.pdf) [accessed : 2017.11.30]
 
6) World Health Organization : WHO treatment guidelines for drug-resistant tuberculosis. (http://apps.who.int/iris/bitstream/10665/250125/1/9789241549639-eng.pdf) [accessed : 2017. 11. 30]
 
7) 医薬品インタビューフォーム デルテイバ (R) 錠
 
8) Matsumoto M, Hashizume H, Tomoshige T, et al : OPC-67683, A Nitro- Dihydro- Imidazooxazole Derivative with promising action against tuberculosis in vitro and in mice. PLoS Medicine 3 : 2131-44, 2006
 
9) Gler MT, Skripconoka V, Sanchez-Garavito E, et al : Delamanid for multidrug- resistant pulmonary tuberculosis. N Engl J Med 366 : 2151-60, 2012
PubMed
10) Skripconoka V, Danilovitis M, Pehme L, et al : Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis. Eur Respir J 41 : 1393-400, 2013
 
11) SIRTURO RHome page. http://www.sirturo.com/
 
12) World Health Organization : The use of bedaquiline in the treatment of multidrug-resistant tuberculosis. (http://apps.who.int/iris/bitstream/10665/84879/1/9789241505482_eng.pdf?ua=1.) [accessed : 2017. 11. 30]
 
13) Andreas H, Alexander Pym, Martin P, et al : Multidrug-resistant tuberculosis and culture conversion with Bedaquiline, N Engl J Med 371 : 723-32, 2014
 
14) Cynamon MH, Klemens SP, Sharpe CA, et al : Activities of several novel oxazolidinones against Mycobacterium tuberculosis in a murine nobel. Antimicrob Agents Chemother 42 : 2674-77, 1999
 
15) Eker B, Ortmann J, Migliori GB, et al : Multidrug- and Extensively Drug-Resistant Tuberculosis, Germany. Emerg Infect Dis 14 : 1700-06, 2008
PubMed
16) Sotgiu G, Centis R, D'Ambrosio L, et al : Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB : systematic review and meta-analysis. Eur Respir J 40 : 1430-42, 2012
PubMed
17) Migliori GB, Eker B, Richardson MD, et al : A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in multidrug-resistant tuberculosis. Eur Respir J 34 : 387-93, 2009
 
18) Javaheri M, Khurana RN, O'Hearn TM, et al : Linezolid-induced optic neuropathy, a mitochondrial disorder? Br J Ophthalmol 91 : 111-15, 2007
PubMed
19) Reddy VM, O'Sullivan JF, Gangadharam PRJ : Antimycobacterial activities of riminophenazines. J Antimicrob Chemother 43 : 615-23, 1999
 
20) Gopal M, Padayatchi N, Metcalfe JZ, et al : Systematic review of clofazimine for the treatment of drugresistant tuberculosis. Int J Tuberc Lung Dis 17 : 1001-7, 2013
PubMed
P.263 掲載の参考文献
1) World Health Organization : Guidelines for treatment of drug-susceptible tuberculosis and patient care, 2017 update. World Health Organization.
PubMed
2) 日本結核病学会編 : 結核診療ガイドライン 改訂第3版. 南江堂, 2015
 
3) 日本結核病学会治療委員会 : 抗結核薬使用中の肝障害への対応について. 結核 82 : 115-8, 2007
 
P.268 掲載の参考文献
1) Scherer K, Brockow K, Aberer W, et al : Desensitization in delayed drug hypersensitivity reactions-an EAACI position paper of the Drug Allergy Interest Group. Allergy 68 : 844-52, 2013
PubMed
2) 日本結核病学会治療委員会 : 抗結核薬の減感作療法に関する提言. 結核 72 : 697-700, 1997
 
3) Kobashi Y, Abe T, Shigeto E, et al : Desensitization therapy for allergic reactions to antituberculous drugs. Intern Med 49 : 2297-301, 2010
PubMed
4) 佐々木結花, 倉島篤行, 森本耕三ほか : 抗酸菌治療薬における急速減感作療法の経験. 結核 89 : 797-802, 2014
Medical*Online
P.272 掲載の参考文献
1) Denning DW, Riniotis K, Dobrashian R, et al : Chronic cavitary and fibrosing pulmonary and pleural aspergillosis : case series, proposed nomenclature change, and review. Clin Infect Dis 37 (Suppl 3) : S265-80, 2003
 
2) Hope WW, Walsh TJ, Denning DW : The invasive and saprophytic syndromes due to Aspergillus spp. Med Mycol 43 (Suppl 1) : S207-38, 2005
 
3) Izumikawa K, Tashiro M, Kohno S : Management of chronic pulmonary aspergillosis. Ann NY Acad Sci1272 : 40-8, 2012
 
4) 深在性真菌症ガイドライン作成委員会 : 深在性真菌症の診断・治療ガイドライン 2014. 協和企画, 2014
 
5) Kohno S, Izumikawa K, Ogawa K, et al : Intravenous micafungin versus voriconazole for chronic pulmonary aspergillosis : a multicenter trial in Japan. J Infect 61 : 410-8, 2010
PubMed
6) Kohno S, Izumikawa K, Yoshida M, et al : A double-blind comparative study of the safety and efficacy of caspofungin versus micafungin in the treatment of candidiasis and aspergillosis. Eur J Clin Microbiol Infect Dis 32 : 387-97, 2013
 
7) 日本医真菌学会アスペルギルス症の診断・治療ガイドライン作成委員会 : アスペルギルス症の診断・治療ガイドライン 2015. 日本医真菌学会, 2015
 
8) Cadranel J, Philippe B, Hennequin C, et al : Voriconazole for chronic pulmonary aspergillosis : a prospective multicenter trial. Eur J Clin Microbiol Infect Dis 31 : 3231-39, 2012
PubMed
9) Tashiro M, Izumikawa K, Minematsu A, et al : Antifungal susceptibilities of Aspergillus fumigatus clinical isolates obtained in Nagasaki, Japan. Antimicrob Agents Chemother 56 : 584-7, 2012
PubMed
10) Kikuchi K, Watanabe A, Ito J, et al : Antifungal susceptibility of Aspergillus fumigatus clinical isolates collected from various areas in Japan. J Infect Chemother 20 : 336-8, 2014
PubMed
P.275 掲載の参考文献
1) Teramoto S, Yoshida K, Hizawa N : Update on the pathogenesis and management of pneumonia in the elderly-roles of aspiration pneumonia. Respir Investig 53 : 178-84, 2015
PubMed
2) Sekizawa K, Matsui T, Nakagawa T, et al : ACE inhibitors and pneumonia. Lancet 352 : 1069, 1998
PubMed
3) Ohkubo T, Chapman N, Neal B, et al, Perindopril Protection Against Recurrent Stroke Sutdy Collaborative Group : Effects of an angiotensin-converting enzyme inhibitor-based regimen on pneumonia risk. Am J Respir Crit Care Med 169 : 1041-5, 2004
 
4) Shinohara Y : Antiplatelet cilostazol is effective in the prevention of pneumonia in ischemic stroke patients in the chronic stage. Cerebrovasc Dis 22 : 57-60, 2006
PubMed
5) 日本呼吸器学会 : 医療・介護関連肺炎診療ガイドライン, メディカルレビュー, 2011 (http://www.jrs.or.jp/home/uploads/photos/1050.pdf) [accessed : 2017. 11. 30]
 
P.280 掲載の参考文献
1) Chen LP, Chen JH, Chen Y, et al : Efficacy and safety of glucocorticoids in the treatment of community-acquired pneumonia : A meta-analysis of randomized controlled trials. World J Emerg Med 6 : 172-8, 2015
PubMed
2) Zhao JN, Liu Y, Li HC : Corticosteroids in treatment of aspiration-related acute respiratory distress syndrome : results of a retrospective cohort study. BMC Pulm Med 16 : 29, 2016
 
3) Marumo S, Teranishi T, Higami Y, et al : Effectiveness of azithromycin in aspiration pneumonia : a prospective observational study. BMC Infectious Diseases 14 : 685, 2014
PubMed
4) Ishida T, Tachibana H, Ito A, et al : Clinical characteristics of nursing and healthcare-associated pneumonia : a Japanese variant of healthcare-associated pneumonia. Intern Med 51 : 2537-44, 2012
PubMed
5) 寺本信嗣 : 誤嚥性肺炎の病態生理. 呼吸器科 10 : 160-6, 2006
 
6) Martin-Loeches I, Lisboa T, Rodriguez A, et al : Combination antibiotic therapy with macrolides improves survival in intubated patients with community-acquired pneumonia. Intensive Care Med 36 : 612-20, 2010
PubMed

VII章 肺循環 / 肺損傷

P.286 掲載の参考文献
1) ARDS Definition Task Force : Acute respiratory distress syndrome : the Berlin Definition. JAMA 307 : 2526-33, 2012
PubMed
2) Lamontagne F, Briel M, Guyatt GH, et al : Corticosteroid therapy for acute lung injury, acute respiratory distress syndrome, and severe pneumonia : A meta-analysis of randomized controlled trials. J Crit Care 25 : 420-35, 2010
PubMed
3) Iwata K, Doi A, Ohji G, et al : Effect of neutrophil elastase inhibitor (sivelestat sodium) in the treatment of acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) : a systematic review and meta-analysis. Intern Med 49 : 2423-32, 2010
PubMed
4) Ogawa Y, Yamakawa K, Ogura H, et al : Recombinant human soluble thrombomodulin improves mortality and respiratory dysfunction in patients with severe sepsis. J Trauma Acute Care Surg 72 : 1150-7, 2012
PubMed
5) Miyoshi S, Ito R, Katayama H, et al : Combination therapy with sivelestat and recombinant human soluble thrombomodulin for ARDS and DIC patients. Drug Des Devel Ther 8 : 1211-9, 2014
PubMed
P.291 掲載の参考文献
1) Ghofrani HA, Grimminger F : Soluble guanylate cyclase stimulation : an emerging option in pulmonary hypertension therapy. Eur Respir Rev 18 : 35-41, 2009
PubMed
2) Goudie AR, Lipworth BJ, Struthers AD, et al : Tadalafil in patients with chronic obstructive pulmonary disease : a randomised, double-blind, parallel-group, placebo-controlled trial. Lancet Respir Med 2 : 293-300, 2014
PubMed
3) Corte TJ, Keir GJ, Wort SJ, et al : Bosentan in pulmonary hypertension associated with fibrotic idiopathic interstitial pneumonia. Am J Respir Crit Care Med 190 : 208-17, 2014
PubMed
4) Tanabe N, Nishimura M, Tatsumi K, et al ; JRS Lung Disease PH Study Group : Multi-institutional retrospective cohort study of patients with severe pulmonary hypertension associated with respiratory diseases. Respirology 20 : 805-12, 2015
 
5) Hoeper MM, Behr J, Gibbs JS, et al : Pulmonary hypertension in patients with chronic fibrosing idiopathic interstitial pneumonias. PLoS One 10, 2015 (e0141911)
PubMed

VIII章 その他

P.297 掲載の参考文献
1) 日本呼吸器学会呼吸器感染症に関するガイドライン作成委員会 : 成人肺炎診療ガイドライン 2017, 日本呼吸器学会, 2017
 
2) Fukusumi M, Chang B, Tanabe Y, et al : Invasive pneumococcal disease among adults in Japan. April 2013 to March 2015 : disease characteristics and serotype distribution. BMC Infect Dis 17 : 2, 2017
 
3) Furumoto A, Ohkusa Y, Chen M, et al : Additive effect of pneumococcal vaccine and influenza vaccine on acute exacerbation in patients with chronic lung disease. Vaccine 26 : 4284-9, 2008
PubMed
4) Kawakami K, Ohkusa Y, Kuroki R, et al : Effectiveness of pneumococcal polysaccharide vaccine against pneumonia and cost analysis for the elderly who receive seasonal influenza vaccine in Japan. Vaccine 28 : 7063-9, 2010
PubMed
5) Maruyama T, Taguchi O, Niederman MS, et al : Efficacy of 23-valent pneumococcal polysaccharide vaccine prevents pneumonia and improves survival in nursing home residents. -A double blind, randomized and placebo controlled trial. BMJ 340 : c1004, 2010
PubMed
6) Bonten MJ, Huijts SM, Bolkenbaas M, et al : Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med 372 : 1114-25, 2015
PubMed
7) 日本呼吸器学会呼吸器ワクチン検討WG委員会/日本感染症学会ワクチン委員会 合同委員会 : 65歳以上の成人に対する肺炎球菌ワクチン接種に関する考え方. (http://www.kansensho.or.jp/guidelines/pdf/o65haienV_171023.pdf) [accessed : 2017. 11. 30]
 
8) Tomczyk S, Bennett NM, Stoecker C, et al : Use of 13-valent pneumococcal conjugate vaccine and 23-valent pneumococcal polysaccharide vaccine among adults aged > 65 years : recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep 63 : 822-5, 2014
PubMed
P.301 掲載の参考文献
1) Vakil N, van Zanten SV, Kahrilas P, et al : The Montreal definition and classification of gastroesophageal reflux disease : a global evidence-based consensus. Am J Gastroenterol 101 : 1900-20, 2006
PubMed
2) el-Serag HB, Sonnenberg A : Comorbid occurrence of laryngeal or pulmonary disease with esophagitis in United States military veterans. Gastroenterology 113 : 755-60, 1997
PubMed
3) 日本呼吸器学会 : 咳嗽に関するガイドライン 第2版. メディカルレビュー, 2012
 
4) 日本アレルギー学会 : 喘息予防・管理ガイドライン 2015. 協和企画, 2015
 
5) Lee JS, Ryu JH, Elicker BM, et al : Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 184 : 1390-4, 2011
PubMed
6) Lee JS, Collard HR, Anstrom KJ, et al : Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis : an analysis of data from three randomised controlled trials. Lancet Respir Med 1 : 369-76, 2013
PubMed
7) Othman F, Crooks CJ, Card TR : Community acquired pneumonia incidence before and after proton pump inhibitor prescription : population based study. BMJ 15 ; 355 : i5813, 2016
 
P.305 掲載の参考文献
1) 日本循環器学会, 日本肺癌学会, 日本癌学会, 日本呼吸器学会編 : 禁煙治療のための標準手順書 第6版. 2014
 
2) 藤原久義, 山本蒔子, 安陪隆明ほか : 若年者の禁煙治療指針. 禁煙会誌 11 : 145-51, 2016
Medical*Online
3) Cahill K, Stevens S, Perera R, et al : Pharmacological interventions for smoking cessation : an overview and network meta-analysis. Cochrane Database of Systematic Reviews 2013, Issue 5. Art. No. : CD009329.
 
4) Bekki K, Inaba Y, Uchiyama S, et al : Comparison of chemicals in mainstream smoke in heat-not-burn tobacco and combustion cigarettes. J UOEH 39 : 201-7, 2017
 

書評

最近チェックした商品履歴

Loading...